Skip to main content

mitogen-activated protein kinase kinase 2

The MAP2K2 gene provides instructions for making a protein known as MEK2 protein kinase. This protein is part of a signaling pathway called the RAS/MAPK pathway, which transmits chemical signals from outside the cell to the cell's nucleus. RAS/MAPK signaling helps control the growth and division (proliferation) of cells, the process by which cells mature to carry out specific functions (differentiation), cell movement, and the self-destruction of cells (apoptosis).

Video picks for Genes
Video library

Normal function

The MAP2K2 gene provides instructions for making a protein known as MEK2 protein kinase. This protein is part of a signaling pathway called the RAS/MAPK pathway, which transmits chemical signals from outside the cell to the cell's nucleus. RAS/MAPK signaling helps control the growth and division (proliferation) of cells, the process by which cells mature to carry out specific functions (differentiation), cell movement, and the self-destruction of cells (apoptosis).

The MAP2K2 gene is very similar to a gene called MAP2K1, which provides instructions for making a protein known as MEK1 protein kinase. Like MEK2 protein kinase, this protein functions as part of the RAS/MAPK signaling pathway. Together, the MEK1 and MEK2 protein kinases appear to be essential for normal development before birth and for survival after birth.

Conditions referring to this gene or chromosome

Other names

dual specificity mitogen-activated protein kinase kinase 2

ERK activator kinase 2

MAP kinase kinase 2

MAPK-ERK Kinase 2

MAPK/ERK kinase 2

MAPKK2

MEK2

mitogen-activated protein kinase kinase 2, p45

MKK2

MP2K2_HUMAN

PRKMK2

Patient picks for Genes

Related patient information and medicines

Myelofibrosis

Patient information leaflet

Myelofibrosis

Myelofibrosis which develops as a complication of other diseases is called secondary myelofibrosis. Myelofibrosis is caused by an abnormality of the developing cells (stem cells) in the bone marrow. It's not known what causes the genetic mutation in blood stem cells. The gene mutation that occurs in most people affected by myelofibrosis is a.

Muscular dystrophy

Patient information leaflet

Muscular dystrophy

Muscular dystrophy is an inherited (genetic) disorder causing muscle weakness. There are different types of muscular dystrophy, which vary as to how severe they are, ranging from very mild to severe. Also, if a child has delayed motor mil... MD may be diagnosed using one or more of the following tests: A blood test Blood tests for creatine kinase.

Juvenile idiopathic arthritis

Patient information leaflet

Juvenile idiopathic arthritis

As they are relatively new medicines, there are still studies being done to establish whether there are any long-term health risks from taking them. Options include: Etanercept Etanercept Tocilizumab Infliximab Abatacept Adalimumab Tofacitinib is another new drug. It belongs to a type of drug called JAK kinase inhibitors. It is sometimes used if.

Primary liver cancer

Patient information leaflet

Primary liver cancer

If you already have cirrhosis and your health becomes worse quite quickly, the cause may be a liver cancer which has developed. Everyone with cirrhosis should be having regular monitoring with an ultrasound and blood tests to detect any development of a liver cancer. There are new medicines being developed for the treatment of liver cancer. For.

Mouth cancer

Patient information leaflet

Mouth cancer

Diagnosing mouth cancer Your healthcare professional may suspect mouth cancer if you have a lesion in your mouth (such as a sore, an ... Dr Krishna Vakharia , 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that a person should receive a diagnosis or ruling out of cancer within 28 days of being.

Mastocytosis and mast cell disorders

Patient information leaflet

Mastocytosis and mast cell disorders

A mast cell is a type of white blood cell. If the condition is severe, surgery to remove the spleen (splenectomy), medicines that have an effect on the immune system (suc... Dr Sarah Jarvis , 28th September 2021 Midostaurin for treating advanced systemic mastocytosis The National Institute for Health and Care Excellence (NICE) has brought out new.

Further reading and references

Article history

The information on this page is written and peer reviewed by qualified clinicians.
  • 18 Aug 2020 | Latest version
  • 1 May 2012 | Originally published

Join the conversation

Share your thoughts or experiences with others in our patient communities.

Disclaimer: The views expressed in the community do not represent medical advice. For any health concerns, consult your GP or healthcare provider.

Online pharmacy, treatments and health services

Simple access to trusted treatments and health services online.

Common conditions

Get help with common conditions through the NHS, without a GP appointment.

Book your free Pharmacy First appointment

Sign up to the Patient newsletter

Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.

Please enter a valid email address

By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.